Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study
16/9 09:33
(RTTNews) - Johnson & Johnson (JNJ) Monday announced positive interim data from the Phase 2 SunRISe-4 study of TAR-200 in combination with cetrelimab in patients suffering from muscle-invasive bladder cancer (MIBC)....